Herpes simplex viruses: Is a vaccine tenable?

Journal of Clinical Investigation

Volumn 110, Issue 2, 2002, Pages 145-151

  Whitley, Richard J ^a,c   Roizman, Bernard ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE;

ENCEPHALITIS; ERYTHEMA MULTIFORME; GENE THERAPY; GENITAL HERPES; HERPES LABIALIS; HERPES SIMPLEX; KERATOCONJUNCTIVITIS; NEWBORN INFECTION; PRIORITY JOURNAL; REVIEW; STOMATITIS; VIRUS REPLICATION;

EID: 0036077408     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0216126     Document Type: Review

References (53)

1. Herpesviridae
2. Herpes simplex viruses and their replication
3. Herpes simplex genes: The blueprint of a successful human pathogen
4. A generically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
5. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture
6. Herpes simplex vaccines
7. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
8. Vaccination for recurrent herpes simplex in infection: Initiation of a new disease site following the use of unmodified material containing the live virus
9. Studies on herpes simplex virus. VI. Observations on patients with recurrent herpetic lesions injected with herpes viruses or their antigens
10. Vaccine therapy in recurrent herpes simplex
11. The value of tissue culture vaccine in the prophylaxis of recurrent attacks of herpetic keratitis
12. Herpes simplex virus, type II: Microbiology and clinical experiences with attenuated vaccine
13. Immunotherapy with inactivated polyvalent herpes vaccines
14. Therapy of recurrent Herpes simplex
15. An attempt to vaccinate against herpes simplex
16. Herpes simplex virus type-2 glycoprotein-subunit vaccine: Tolerance and humoral and cellular responses in humans
17. Efficacy of a nucleic acid free herpetic subunit vaccine
18. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine
19. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD
20. Protection of mice from lethal herpes-simplex virus-infection by vaccination with a secreted form of cloned glycoprotein-D
21. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: Protection against challenge with virulent virus
22. Vaccination with recombinant herpes simplex virus glycoproteins: Protection against initial and recurrent genital herpes
23. Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: Factors influencing efficacy
24. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D
25. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for a genital herpes infection
26. Development of herpes simplex virus subunit vaccine
27. Genetic variability, of herpes simplex virus: Development of a pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 virus strain in mouse brain
28. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
29. Gender-specific efficacy of a prophylactic SBAS4-adjuvanted gD2 subunit vaccine against genital herpes disease (GHD): Results of two clinical efficacy trials
30. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen
31. Construction of live vaccines using genetically engineered poxviruses: Biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D
32. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice
33. Expression of herpes simplex virus 1 glycoprorein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus infection
34. Protection of mice against lethal challenge with herpes simplex virus by vaccination with an adenovirus vector expressing HSV glycoprotein B
35. A generalized technique for deletion of specific genes in large genomes: Alpha gene 22 of herpes simplex virus 1 is not essential for growth
36. Molecular engineering of the herpes simplex virus genome: Insertion of a second L-S junction into the genome causes additional genome inversions
37. In vivo behavior of genetically engineered herpes simplex virus R7017 and R7020. Construction and evaluation in rodents
38. Phase 1 trial of R7020: A live attenuated recombinant herpes simplex (HSV) candidate vaccine
39. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection
40. Comparison of the intranuclear distributions of herpes simplex virus proteins involved in various viral functions
41. Experimental therapy of human glioma by means of a genetically engineered virus mutant
42. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleoride reductase
43. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma
44. CNS tumor therapy by attenuated herpes simplex viruses
45. Engineered herpes simplex virus expressing interleukin 12 in the treatment of experimental murine tumors
46. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors
47. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1
48. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
49. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma
50. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
51. Genetically engineered HSV in the treatment of glioma: A review
52. Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trial
53. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma